Outcomes of Patients Who Are BCMA (B-cell maturation Antigen) Directed Therapy (BDT) Exposed Vs BCMA Naive in Penta-Relapsed Refractory Multiple Myeloma (RRMM)

被引：1

作者：

Mammadzadeh, Aytaj ^{[1
]}

Peng, Fulei ^{[2
]}

Atrash, Shebli ^{[3
,4
]}

Hashmi, Hamza ^{[3
,5
]}

Mohan, Meera ^{[3
,6
]}

Alkharabsheh, Omar ^{[3
,7
]}

Afrough, Aimaz ^{[3
,8
]}

Cui, Wei ^{[3
,9
]}

Mahmoudjafari, Zahra ^{[3
,10
]}

Abdallah, Al-Ola ^{[11
,12
]}

机构：

[1] Azerbaijan Med Univ, Dept Internal Med, Baku, Azerbaijan

[2] Mercy St Louis Hosp, Dept Internal Med, St Louis, MO USA

[3] US Myeloma Res Innovat Res Collaborat USMIRC, Westwood, KS USA

[4] Atrium Hlth, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA

[5] Med Univ South Carolina, Dept Hematol Med Oncol, Charleston, SC 29425 USA

[6] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[7] Univ S Alabama, Mitchell Canc Inst, Div Hematol Oncol, Mobile, AL USA

[8] UT Southwestern Med Ctr, Div Hematol Malignancies & Cellular Therapy, Dept Internal Med, Harold C Simmons Comprehens Canc Ctr, Dallas, TX USA

[9] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA

[10] Univ Kansas, Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Kansas City, KS 66103 USA

[11] Univ Kansas, Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Westwood, KS USA

[12] US Myeloma Innovat Res Collaborat USMIRC, Westwood, KS USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-165762

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：4277 / 4278

页数：2

共 50 条

[41] Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2020
Demel, Ivo
Bago, Julio Rodriguez
Hajek, Roman
Jelinek, Tomas
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (04) : 705 - 722
[42] Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma (RRMM)
Theprungsirikul, Poy
Yu, Mansen
Liu, Yuxin
Rall, Kerri
Matthews, Martin
Neparidze, Natalia
Parker, Terri
Browning, Sabrina
Anderson, Tara
Stevens, Erica
Foss, Francine
Gowda, Lohith
Pillai, Manoj
Isufi, Iris
Seropian, Stuart
Mirza, Sayeef
Bar, Noffar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S92 - S93
[43] POPULATION PHARM ACOKINETICS (POPPK) OF ABBV-383, A B-CELL MATURATION ANTIGEN (BCMA) x CD3 BISPECIFIC T-CELL-REDIRECTING ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Polepally, A.
Badillo, J.
Rinas, M.
Ahsan, A.
Bueno, O.
Talati, C.
Menon, R.
Engelhardt, B.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S69 - S69
[44] Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Lesokhin, Alexander M.
Levy, Moshe Y.
Dalovisio, Andrew P.
Bahlis, Nizar J.
Solh, Melhem
Sebag, Michael
Jakubowiak, Andrzej
Jethava, Yogesh S.
Costello, Caitlin L.
Chu, Michael P.
Savona, Michael R.
Gasparetto, Cristina
Trudel, Suzanne
Chou, Jeffrey
Udata, Chandrasekhar
Basu, Cynthia
Krupka, Heike I.
Raje, Noopur S.
BLOOD, 2020, 136
[45] Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed/refractory multiple myeloma
Chen, Dongjian
Wang, Xiaoxiang
Chen, Zhi
Jiang, Songfu
Jiang, Hua
Fu, Weijun
Xiang, Fang
Sun, Xuedong
Du, Juan
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (12) : E478 - E481
[46] Correlative biomarker analyses for optimal therapeutic dose determination of ABBV-383, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
Ahsan, Aarif
Mantis, Christine
Luo, Xizhi
Zhang, Catherine C.
Valdes, Cesar Rodriguez
Voorhees, Peter M.
D'Souza, Anita
Chung, Alfred
Tuchman, Sascha
Safah, Hana
Mckay, John T.
Weisel, Katja C.
Teipel, Raphael
Korde, Neha
Vij, Ravi
Kumar, Shaji
Bueno, Orlando Felix
Pothacamury, Rajvineeth Kumar
Talati, Chetasi
Ross, Jeremy A.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[47] Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).
Bahlis, Nizar J.
Raje, Noopur S.
Costello, Caitlin
Dholaria, Bhagirathbhai R.
Solh, Melhem M.
Levy, Moshe Y.
Tomasson, Michael H.
Dube, Harman
Liu, Feng
Liao, Kai Hsin
Basu, Cynthia
Skoura, Athanasia
Chan, Edward Michael
Trudel, Suzanne
Jakubowiak, Andrzej J.
Chu, Michael P.
Gasparetto, Cristina
Dalovisio, Andrew
Sebag, Michael
Lesokhin, Alexander M.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[48] Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.
Berdeja, Jesus G.
Madduri, Deepu
Usmani, Saad Zafar
Singh, Indrajeet
Zudaire, Enrique
Yeh, Tzu-Min
Allred, Alicia J.
Olyslager, Yunsi
Banerjee, Arnob
Goldberg, Jenna D.
Schecter, Jordan
Geng, Dong
Wu, Xiaoling
Carrasco-Alfonso, Marlene
Rizvi, Syed
Fan, Frank
Jakubowiak, Andrzej J.
Jagannath, Sundar
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[49] Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T therapy
Van Oekelen, Oliver
Mouhieddine, Tarek
Pan, Darren
Metzger, Megan
Agte, Sarita
Aleman, Adolfo
Melnekoff, David
Lancman, Guido
Lagana, Alessandro
Richard, Shambavi
Sanchez, Larysa
Richter, Joshua
Cho, Hearn Jay
Chari, Ajai
Jagannath, Sundar
Parekh, Samir
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S38 - S38
[50] Early Experience with Salvage RT for Relapsed / Refractory Multiple Myeloma Following BCMA-Directed CART Cell Therapy
Dreyfuss, A.
Fregonese, B.
Mailankody, S.
Usmani, S.
Imber, B. S.
Yahalom, J.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E618 - E618

← 1 2 3 4 5 →